| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z |
|
| A |
Agonist |
A drug capable of combining with receptors to initiate drug actions |
|
Amino acid |
Building block of peptides/proteins |
|
Analogue |
Similar in chemical and physical structure |
|
| B |
|
|
|
| C |
|
|
|
| D |
Deslorelin |
Peptide analogue of GnRH |
|
DNA |
Short for deoxyribonucleic acid, a molecule that encodes operating instructions for our bodies |
|
| E |
|
|
|
| F |
FDA |
The Food and Drug Administration, the U.S. government pharmaceuticals regulatory body |
|
FSH |
Follicle-Stimulating Hormone |
|
| G |
GnRH |
Gonadotropin-Releasing Hormone |
|
Gonadotropin |
Hormone capable of promoting gonadal growth and function |
|
| H |
hCG |
human Chorionic Gonadotropic hormone |
|
Hormone |
Proteins that are chemical messengers in the body |
|
| I |
Immunogenic |
Having properties of an antigen i.e. able to stimulate an immune response |
|
Immunoglobulin |
An antibody protein. There are five different types, known as IgG, IgA, IgD, IgM and IgE. The immunoglobulin used in both Enbrel and Remicade is IgG |
|
Immunosuppressant |
A drug that suppresses the natural functioning of the immune system, used mainly to reduce the chance of rejection of a transplanted organ |
|
| J |
|
|
|
| K |
|
|
|
| L |
Lead |
A treatment idea that has shown enough promise to warrant being followed up some more |
|
LH |
Luteinizing hormone |
|
| M |
|
|
|
| N |
National Phase |
The taking of a PCT Application to an individual patent office Notice of Allowance Advice from the U.S. Patent Office of that Office's intention to grant a patent |
|
NRA |
National Regulatory Authority (Australia) |
|
| O |
Oestrous |
Period of maximal readiness for reproduction of female animals |
|
| P |
PCT Application |
An application for a patent under the rules of the Patent Cooperation Treaty; that patent provides the 'common platform', from which applications for patents can be made to the individual national patent offices |
|
Peptide |
Two or more amino acids linked by chemical bonds |
|
Phase |
One of several trials a drug makes on the road to being approved. Broadly speaking Phase I is designed to test if the drug is safe, Phase II if it is efficacious in a small sample and Phase III if it is efficacious in a large sample |
|
Pipeline |
The drug candidates a company has in its portfolio at various stages of clinical or pre-clinical work |
|
Placebo |
An inert substance given as a medicine during clinical trials for its suggestive effect |
|
Platform |
A collection of technologies that speeds the task of drug research |
|
Polypeptide |
A chain of peptides |
|
Priority Date |
The date on which a provisional application for a patent was first filed |
|
Prostaglandins |
Hormones involved in reproduction, inflammation and other body processes |
|
Protein |
A class of fairly common molecules in the human body that includes antibodies hormones and enzymes |
|
| Q |
|
|
|
| R |
Recombinant DNA |
DNA that has been cut and spliced in order to alter the genetic code (introduce a gene(s) that codes for a protein not normally found in the organism) |
|
| S |
Subcutaneous |
Beneath the skin |
|
| T |
Target |
A disease, or cause of a disease that a drug development team is aiming to develop treatments for. |
|
TGA |
Therapeutic Goods Authority (Australia) |
|
| U |
|
|
|
| V |
|
|
|
| W |
|
|
|
| X |
|
|
|
| Y |
|
|
|
| Z |
|
|
|
|
|
